Drug Profile
Research programme: chimeric antigen receptor T-cell therapy - Helix BioPharma\ProMab Biotechnologies
Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Helix BioPharma; ProMab Biotechnologies
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies; Multiple myeloma; Solid tumours
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Multiple-myeloma in Canada (Parenteral)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Haematological-malignancies in Canada (Parenteral)